Mortality in dialysis patients with cinacalcet use: A large observational registry study.

CONCLUSIONS: Our data suggest that a subgroup of dialysis patients, namely those with moderate sHPT, younger age and without diabetes benefit from cinacalcet with reduced overall and cardiovascular mortality. These findings may help to identify populations for further controlled trials and may allow a more individualized sHPT treatment using cinacalcet in specific patient subgroups. PMID: 28499709 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/28499709?dopt=Abstract

Source: European Journal of Internal Medicine - May 9, 2017 Category: Internal Medicine Authors: Friedl C, Reibnegger G, Kramar R, Zitt E, Pilz S, Mann JFE, Rosenkranz AR Tags: Eur J Intern Med Source Type: research